Oncosil Medical (OSL) FDA announcement summary

Introduction and purpose

• OncoSil device received FDA Humanitarian Device Exemption (HDE) approval for treating distal cholangiocarcinoma (dCCA), completing the regulatory process and granting U.S. marketing authorization.

• OncoSil is the first and only FDA-approved Class III device for dCCA, a rare and aggressive bile duct cancer with limited treatment options.

Details of approval or decision

• HDE approval allows commercial marketing in the U.S. for unresectable, non-metastatic dCCA as an adjunct to systemic therapy in patients over 21.

• Approval restricts initial commercial use to five centers and 30 patients until completion of a post-approval study (PAS).

• FDA approval was granted on August 14, 2026.

Impact on industry and stakeholders

• Opens a new treatment pathway for dCCA patients, addressing a high unmet medical need.

• Estimated total addressable market is AUD 80 million annually, with about 1,000 eligible U.S. patients per year.

• Approval enhances partnering opportunities and is expected to attract industry attention.